N/A N=102 Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device (IUD) After Vaginal Delivery
Contraception
Primary: IUD Usage Rate at 6 Months — 43; 39 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=100 Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia
Cardiovascular Disease
Primary: The Effect of Omega-3 Fatty Acid Supplementation on Cytokine Production (Plasma Levels of TNFα) During an in Vivo Inflammatory Challenge (LPS). — 0.95; 1.26; 1.14; 1.12…
N/A N=17 Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia
Hypoglycemia
Primary: Glucose (mg/dL) — 56.5; 52.8; 55.0; 52.8 mg/dL
Phase 2 N=135 A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 38.4; 24.1 weeks
N/A N=22 A Pilot and Feasibility Study of Mobile-Based Asthma Action Plans
Asthma
Primary: Mobile Asthma Action Plan (AAP) Usage — 4.3 days per week
N/A N=18 Protocol for Staged Stereotactic Radiosurgery for Large Arteriovenous Malformations
Intracranial Arteriovenous Malformations (AVM)
Primary: Number of Participants With Presence of T2 Weighted Changes on Serial MRI Exam Associated With New Neurological Symptoms — 2 participants
N/A N=412 The EVOLVE China Clinical Trial
Coronary Artery Disease
Primary: The In-stent Late Loss Measured by Quantitative Coronary Angiography — 0.20; 0.17 mm
N/A N=20 Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome
Fragile X Syndrome
Primary: Change From Baseline of ABC Irritability Subtest Score at 8 Weeks — -14.37 units on a scale
N/A N=40 An RCT Comparing Xenograft and Allograft for Ridge Preservation
Tooth Loss
Primary: Bone Ridge Buccal-Lingual and Apico-Coronal Measures at 6 Months — 4.95; 6.71; 5.29; 6.24 mm
Phase 2 N=11 Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
PANCREAS · Neuroendocrine
Primary: Overall Response. — 6; 2 participants
N/A N=90 A Retrospective Study Evaluating the Use of the SoloPath® Sheath in Reducing Vascular and Bleeding Complications
Vascular Access Complication
Primary: Vascular Access Site Complications — 17 participants
Phase 2 N=66 Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Multiple Myeloma
Primary: Objective Response (OR) Rate — 0.41 proportion of participants
Phase 3 N=252 Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
HIV · HIV Infections
Primary: Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24 — 55.6; 60.2; -0.4; -0.3 mL/min
Phase 2 N=38 Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
Renal Cancer
Primary: Number of Participants With Adverse Events Associated With Vaccination With Mature DC/Tumor Fusion and GM-CSF — 12 participants
N/A N=651 Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"
Breast Cancer
Primary: Number of Participants Reporting One or More Adverse Drug Reactions — 128 participants